智通财经APP获悉，昭衍新药(06127)涨超5%，截至发稿，涨5.06%，报25.74港元，成交额1.16亿港元。
消息面上，近日，昭衍新药发布年报业绩预告称，预计2025年实现归属于上市公司股东的净利润约2.33亿元到3.49亿元，同比增长约214.0%到371.0%。对于净利润上涨的原因，昭衍新药在公告中指出，本报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩做出积极贡献。具体来看，生物资产公允价值变动贡献的净利润约4.52亿元到5亿元。
今年1月，粤开证券资深投资顾问尹红飞在接受媒体采访时指出，一款新药从实验室到临床，平均要消耗60只（实验猴），大分子药物用量还要翻倍。此外，他还提到，据近期市场报道和方正证券的测算，核心品种食蟹猴单只价格一个月内就飙升到12万~13万元，部分紧俏货源已经报至15万元，比两个月前涨了30%以上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.